FDA approves first Hodgkin lymphoma drug in 30 years

Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL) are two rare but “curable” blood cancers; Hodgkin lymphoma has an 86 percent survival rate and ALCL has an 80 percent survival rate. But what about the other side of the equation – the small population of patients that don’t respond to the standard therapy for these diseases, you might ask? It’s been a tough nut to crack, until now.

For the first time in more than 30 years, there’s hope for this small subgroup of patients. The FDA recently fast-tracked and approved Adcetris, an antibody drug that targets a specific site on lymphoma cells. Adcetris is designed for post-stem cell transplant patients and patients whose cancer resists 1-2 rounds of chemotherapy.

It’s a new day for Hodgkin lymphoma and ALCL patients.

For more information about Hodgkin lymphoma and ALCL, visit www.lls.org.  


About Megan Kilkenny

LLS Sr. Director, Marketing Communication Team In Training Alum Three-time Nike Women's Half Marathon finisher
This entry was posted in Blood Cancer Research, General SF Chapter and tagged . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s